Trials / Recruiting
RecruitingNCT06355739
CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+
Phase II Clinical Study on the Safety and Efficacy of Autotransfusion Agents Targeting CD19 Chimeric Antigen Receptor T Lymphocytes (BIC-19GG, BIC-2019,BIC-2219)in the Treatment of CD19-positive Children With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Zhu Xiaofan · Academic / Other
- Sex
- All
- Age
- 3 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and efficacy of BIC-19GG, BIC-2019, BIC-2219 in the treatment of relapsed/refractory B acute lymphoblastic leukemia/lymphoblastic lymphoma in children
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | CAR T cell injection | intravenous injection |
Timeline
- Start date
- 2024-02-01
- Primary completion
- 2026-12-01
- Completion
- 2027-01-15
- First posted
- 2024-04-09
- Last updated
- 2024-04-09
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06355739. Inclusion in this directory is not an endorsement.